Yuping Shen
Tongji University
5 Papers
4 Citations
Yuping Shen is an academic researcher from Tongji University. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Shun Lu,Lin Wu,Hong Jian,Ying Cheng,Qing Wang,Jian Fang,Ziping Wang,Yanping Hu,L.N. Han,Meili Sun,Liyun Miao,Cuimin Ding,Jiuwei Cui,Ke Wang,Baolan Li,Xing-Ya Li,Feng Ye,Anwen Liu,Yueyin Pan,Shundong Cang,Huilin Zhou,Xing-Yu Sun,Yuping Shen,Shuyan Wang,Wen Xiao Zhang,Yue He +25 more
TL;DR: In the ORIENT-31 trial as discussed by the authors , sintilimab plus IBI305 plus chemotherapy (pemetrexed and cisplatin) significantly improved progression-free survival in patients with EGFR-mutated non-squamous non-small-cell lung cancer (NSCLC) who progressed on EGFR tyrosine-kinase inhibitor treatment.
78
The establishment of a new medical model for tumor treatment combined with Watson for Oncology, MDT and patient involvement.
Juemin Fang,Zhongzheng Zhu,Hui Wang,Fei Hu,Zhuqing Liu,Xianling Guo,Jianhua Chen,Chunyan Li,Yuping Shen,Qing Xu +9 more
TL;DR: A cognitive computing system developed by IBM to assist in tumor therapy which was trained by the Memorial Sloan Caitlin Cancer Center (MSKCC) for fou...
4
Abstract CT030: Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study
Qiang Zhou,Nong Yang,Jun Zhao,Yang Yu,Ying Yuan,Huijuan Wang,Xing-Ya Li,Xiaorong Dong,Hongmei Zhang,Dingzhi Huang,Qian Chu,Sujie Zhang,Mengna Huang,Yuping Shen,Yi-Long Wu +14 more
TL;DR: In this article , the authors reported that IBI351 (GFH925) was well-tolerated and demonstrated promising efficacy in patients with advanced solid tumors harboring KRAS p.G12C mutation.
2
Hematologic toxicity of gemcitabine: a comparison between fixed-dose rate infusion and thirty-minute infusion in the treatment of malignancy
TL;DR: Hematologic toxicity of gemcitabine therapy at a fixed-dose rate for malignancy is tolerable and the result showed that the grades 3–4 leucopenia was significantly different between the two arms.
Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients
TL;DR: Patients with grades 1 and 2 HSRs can successfully rechallenge with oxaliplatin and complete their treatment by premedication with dexamethasone and antihistamine, and attention should be paid to patients with any prior exposure to oxali Platin.